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Abstract 
Objectives: There is still little evidence to support routine dual antiplatelet therapy (DAPT) 
with P2Y12 antagonists following coronary artery bypass grafting (CABG). The Arterial Revas-
cularization Trial (ART) was designed to compare 10-year survival after bilateral versus single 
internal thoracic artery grafting. We aimed to get insights into the effect of DAPT (with 
clopidogrel) following CABG on 1 year outcomes by performing a post-hoc ART analysis.  
Methods: Among patients enrolled in the ART (n=3102), 609 (21%) and 2308 (79%) were 
discharged on DAPT or aspirin alone respectively. The primary endpoint was the incidence of 
major adverse cerebrovascular and cardiac events (MACCE) at 1 year including cardiac death, 
myocardial infarction, cerebrovascular accident and reintervention; safety endpoint was bleed-
ing requiring hospitalization. Propensity score (PS) matching was used to create comparable 
groups.  
Results: Among 609-PS matched pairs, MACCE occurred in 34 (5.6%) and 34 (5.6%) in the 
DAPT and aspirin alone groups respectively with no significant difference between the two 
groups (HR 0.97; 95%CI 0.59-1.59; P=0.90). Only 188 (31%) subjects completed 1 year of 
DAPT and in this subgroup, MACCE rate was 5.8% (HR 1.11; 95%CI 0.53-2.30; P=0.78).  In 
the overall sample, bleeding rate was higher in DAPT group (2.3% versus 1.1%; P=0.02) alt-
hough this difference was no longer significant after matching (2.3% vs 1.8%; P=0.54).   
Conclusions: Based on these findings, when compared to aspirin alone, DAPT with 
clopidogrel prescribed at discharge was not associated with a significant reduction of adverse 
cardiac and cerebrovascular events at 1 year following CABG.  
Keywords: dual antiplatelet therapy; coronary artery bypass grafting; bleeding
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Introduction 
Coronary artery bypass grafting (CABG) is widely regarded as the revascularisation strategy 
of choice, particularly in patients with multivessel coronary artery disease [1]. However, 
CABG patients still have a significant risk of subsequent major adverse cardiovascular events 
(MACCE, including mortality, myocardial infarction (MI) stroke and repeat revacularization) 
secondary to graft failure and atherosclerosis progression, particularly during the first 12 
months. In fact, MACCE rates in the first year after CABG still exceed 12% [2] 
The appropriate antiplatelet regimen after CABG remains an area of controversy [3]. Dual 
antiplatelet therapy (DAPT) with the addition of an oral P2Y12 antagonist such as Clopidogrel 
to aspirin for 1 year after surgery has been proposed to improve outcomes. Plaque stability, 
prevention of graft closure, and secondary thrombosis form the basis for using a second an-
tiplatelet drug, whereas the increased risk of bleeding and lack of conclusive evidence should 
also be considered.  
Evidence for use of DAPT following CABG [4] is based mainly on a small proportion of pa-
tients undergoing surgical revascularization in landmark trials enrolling acute coronary syn-
drome (ACS) patients [5-7]. Whereas cardiac surgeons are very familiar with the guidelines 
regarding discontinuation of DAPT prior to CABG to minimize bleeding risks [8,9], there is 
considerable variability in DAPT resumption in post CABG [10,11]. 
The Arterial Revascularization Trial (ART) was designed to investigate whether bilateral in-
ternal thoracic artery (BITA) grafting is associated with improved 10-year survival when com-
pared to single internal thoracic artery (SITA) grafting in patients with multivessel disease 
undergoing CABG [12] and final results will be available in 2018. We aimed to get insights 
into the efficacy and safety of DAPT following CABG on 1 year outcomes by performing a 
retrospective analysis of the ART trial.  
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Materials and Methods 
This research adheres to the principles set forth in the Declaration of Helsinki 
(http://www.wma.net/en/30publications/10policies/b3/index.html). For the purpose of the pre-
sent analysis, patients enrolled in the ART (n=3102) were classified according to whether they 
were discharge on DAPT (with clopidogrel) or aspirin alone following surgery. In the ART, 
antiplatelet therapy prescribed at discharge was at discretion of responsible physicians. We 
excluded those who met the following criteria: 1) Hospital death; 2) Withdrawn; 3) No infor-
mation on antiplatelet therapy at discharge; 4) Clopidogrel alone at discharge. 
Trial design 
The protocol for the ART has been published [13]. Briefly, the ART is a 2-arm, randomized 
multicenter trial conducted in 28 hospitals in 7 countries, with patients being randomized 
equally to SITA or BITA grafts. Eligible patients were those with multivessel coronary artery 
disease undergoing CABG including urgent patients. Emergency patients (on-going myocar-
dial ischemia/cardiogenic shock) and those requiring single grafts or redo CABG were ex-
cluded.  
Follow-up and Study Endpoints  
Questionnaires were sent to study participants by post at 1 year after surgery. No clinic visits 
were planned apart from the routine clinical 6-week post-operative visit. Participants were sent 
stamped addressed envelopes to improve the return rates of postal questionnaires. Study co-
ordinators contacted participants by telephone to alert them to the questionnaire’s arrival and 
to ask them about medications, adverse events and health services resource use. 
The primary endpoint was the incidence of major adverse cerebrovascular and cardiac events 
(MACCE) at 1 year defined as the occurrence of cardiovascular death (CV-death), myocardial 
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infection (MI), either ST elevation or non ST elevation MI, cerebrovascular accident (CVA) or 
repeat revascularization. We also investigated the composite endpoint of cardiac death, MI and 
CVA and all-cause mortality. Safety endpoint was bleeding requiring re-hospitalization. Ad-
verse events were adjudicated blind to surgical procedure by a member of the Clinical Event 
Review Committee. Follow-up at 1 year was available for all patients included in the analysis 
(100%).  
Statistical analysis 
Multiple imputation was used to address missing data (http://www.jstatsoft.org/v45/i07/). Ex-
pectation-maximization with bootstrapping algorithm was used to generate 3 imputed datasets. 
No prior information was used. Sets of estimates from different datasets were combined using 
the Rubin rule: the central estimate corresponds to the mean of individual imputation estimates 
and the variance is the weighted sum of two variances: the within imputation variance and the 
between imputation variance [14]. Due to lack of randomization with regards to DAPT admin-
istration following surgery, a propensity score (PS) was generated for each patient from a mul-
tivariable logistic regression model based on pre-treatment covariates as independent variables 
with DAPT versus aspirin alone administration as a binary dependent variable [15]. Covariates 
included in the PS model were: age, female gender, body mass index (BMI), creatinine, diabe-
tes mellitus (DM), smoking, chronic obstructive pulmonary disease (COPD), peripheral vas-
cular disease (PVD), left ventricular ejection fraction (LVEF), left main disease (LMD), myo-
cardial infarction (MI, including both ST elevation and non ST elevation MI), percutaneous 
coronary intervention (PCI), unstable angina (UA), off-pump CABG (OPCAB), use of saphe-
nous vein graft (SVG), other medication prescribed at discharge: vitamin K antagonist (VKA), 
beta-blockers (BB), angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor 
blocker (ARB).  
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Pairs of patients were derived using greedy 1:1 matching with a calliper of width of 0.2 stand-
ard deviation of the logit of the PS (http://CRAN.Rproject.org/package=nonrandom). The qual-
ity of the match was assessed by comparing selected pre-treatment variables in propensity 
score–matched patients using the standardized mean difference (SMD), for which an absolute 
standardized difference of greater than 10% is suggested to represent meaningful covariate 
imbalance [16]. A Cox regression model, stratified on the matched pairs [14] and adjusted for 
other medications at discharge, was used to estimate the treatment effect (i.e. DAPT vs aspirin 
alone) on outcomes of interest (http://CRAN.R-project.org/package=survival). This approach 
accounts for the within-pair homogeneity by allowing the baseline hazard function to vary 
across matched sets. For competing risk adverse event (MI, CVA and repeat revascularization) 
a competing risk framework was used (https://CRAN.R-project.org/package=riskRegression). 
Potential effect modifiers (interaction terms) examined were: 1) unstable angina, 2) prior MI 
within 1 year; 3) prior percutaneous coronary intervention (PCI) within 1 year; 4) off-pump 
surgery; and 5) use of saphenous vein graft (SVG). Double robust method (multivariate adjust-
ment in the PS matched sample) was used to compute treatment effect estimates within sub-
groups. The proportional hazard assumption was tested by graphical inspection using log(-
log(S)) method with Kaplan Meier estimators from the PS matched sample. In this case, the 
space between the two curves should be constant over time (Supplementary Figure 1 for the 
primary endpoint). A goodness of fit test (Schoenfeld residuals) was used to confirm that re-
siduals for the treatment variable were not related to time (P=0.49 for the primary endpoint). 
A generic binomial test was used for a post-hoc power calculation for the primary end-point. 
Time to event analysis were graphically presented as cumulative incidence curves which show 
the cumulative probabilities of experiencing the event of interest. Cumulative incidence was 
computed as 1-St where St corresponds to the proportion surviving past interval t) obtained 
from the life table using the Kaplan-Meier approach. All p-values <0.05 were considered to 
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indicate statistical significance. All statistical analysis were performed using R Statistical Soft-
ware (version 3.2.3; R Foundation for Statistical Computing, Vienna, Austria). 
Results 
The final study population consisted of 2917 patients. Of them 609 (21%) and 2308 (79%) 
were discharged on DAPT or aspirin alone respectively. Baseline characteristics of the two 
groups are reported in Table 1. In particular, patients receiving DAPT were more likely to have 
unstable angina and to receive clopidogrel preoperatively. Patients discharged on DAPT were 
more likely to have off-pump surgery, to receive SVG and to be discharged on statins and 
ACEI/ARB. The use of vitamin K antagonists at discharge was higher in the aspirin group 
(Figure 1). After PS matching the two groups were comparable for all pre-treatment variables 
investigated (Figure 1).  
Efficacy endpoints  
Efficacy endpoints in the 609-PS matched pairs are reported in Table 2. The rate of MACCE 
was 34 (5.6%) and 34 (5.6%) in the DAPT and aspirin alone groups respectively with no sig-
nificant difference between the two groups (HR 0.97; 95%CI 0.59-1.59; P=0.90; Figure 2 left). 
The rate of the composite of CV death, MI and stroke was 21 (3.5%) and 29 (4.8%) in the 
DAPT and aspirin alone groups (HR 0.71; 95%CI 0.40-1.27; P=0.20; Figure 2 right).  
None of the possible effect modifiers showed a significant interaction with MACCE: unstable 
angina (β=-0.39±0.70; P=0.57); prior MI (β=0.1 ±0.87; P=0.98) or prior PCI within 1 year (β=-
0.04±1.55; P=0.97), OPCAB (β=-0.82±0.69; P=0.23) and use of saphenous vein grafts (β=-
0.35±0.97; P=0.71). However, unstable angina, OPCAB and the use of SVG showed larger 
coefficients in favor of a benefit from DAPT. In particular, in patients with unstable angina, 
DAPT did not significantly influence the risk of MACCE (HRDR 0.90; 95%CI 0.40-2.06; 
P=0.81) but was associated with a lower risk for the composite of CV death, MI and CVA 
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(HRDR 0.42; 95%CI 0.15-1.21; P=0.1). In patients undergoing off-pump surgery, DAPT did 
not significantly influence the risk of MACCE (HRDR 0.90; 95%CI 0.50-1.63; P=0.73) but was 
associated with a lower risk for the composite of CV death, MI and CVA (HRDR 0.53; 95%CI 
0.25-1.11; P=0.09). 
Among 609 patients who received DAPT postoperatively, 188 (31%) completed 1 year of 
DAPT, 362 (59%) switched to aspirin alone and other 24 (4%) switched to Clopidogrel alone 
(unknown for the remaining 35 patients). The rate of MACCE and the composite of CV death, 
MI and CVA was 5.8% and 2.7% respectively for those who continued DAPT for 1 year, 3.9% 
and 1.7% respectively for those who switched to aspirin alone and 12.5% and 8.3% respec-
tively for those who switched to clopidogrel alone. We the analysis was restricted to subjects 
who continued DAPT for 1 year (n=188), DAPT did not significantly influence MACCE 
(HRDR 1.11[0.53-2.30]; P=0.78) or the composite of death, MI and CVA (HRDR 0.62; 95%CI 
0.22-1.69; P=0.34).  
Post-hoc power calculation was based on a 2.0 percentage point reduction in MACCE (3.5% 
with DAPT vs 5.5% with Aspirin alone) accordingly to a pooled analysis recently published 
[3]. The power achieved was 90% (sample size 1218, 5% significance, 2 tails; Supplementary 
Figure 2). 
Safety endpoint 
The rate of major bleeding was significantly higher in patients discharged on DAPT (14/609, 
2.3%) when compared to aspirin alone (25/2308, 1.1%) (HR 2.14[1.11-4.11]; P=0.02; Figure 
3) although this difference was no longer significant after PS matching (14,2.3% vs 11,1.8%; 
HR 1.30; 95%CI 0.58-2.8; P=0.54).   
Discussion 
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Based on the present post-hoc analysis there is no evidence that DAPT with Clopidogrel can 
significantly reduce the rate of MACCE following surgery. However, in subjects admitted with 
unstable angina and undergoing off-pump surgery, we found a non-significant trend towards a 
larger protective effect from DAPT. DAPT at discharge was associated with an increased risk 
of bleeding but bleeding rates were particularly low in both groups.  
Definitive guideline recommendations regarding use of DAPT after CABG are currently lack-
ing. Evidence for use of DAPT following CABG is based mainly on a small proportion of 
patients in three landmark trials enrolling ACS patients [17-19]. Those trials were not ade-
quately powered to address the role of DAPT in the post-CABG cohort. Another limitation is 
that they studied three different oral P2Y12 antagonists: Clopidogrel, Ticagrelor and Presugel. 
Moreover these results are based on post-randomization subsets from single RCTs in which 
DAPT was initiated prior to CABG. Therefore the decision to undergo CABG is a post ran-
domization event occurring at variable times post randomization. This decision can thus be 
influenced by randomized group resulting in potential baseline imbalances between interven-
tion and control groups. On the other hand, available trials on DAPT enrolling CABG patients 
only present limited design and are largely underpowered to detect significant differences [20-
25].   
Patients were enrolled into ART from 2004 to 2007 and Clopidogrel was the only P2Y12 antag-
onist used in this trial. Prasugrel and Ticagrelor were approved for use in Europe 2009 and 
2010 respectively and the question whether DAPT with newer P2Y12 antagonists is more effec-
tive remains to be determined. Of note, a recent meta-analysis [3] including 4 CABG-sub-
groups ACS RCTs [17-20] (n=3901) and 5 post-elective CABG trials [21-25] (n=986) con-
cluded that DAPT resumption with higher intensity P2Y12 antagonists (Prasugrel or Ticagre-
lor), but not Clopidogrel, reduces all-cause mortality in ACS patients who have undergone 
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CABG. In the ART trial the vast majority of patients with prior MI within 1 year were dis-
charged on aspirin alone in contrast with current recommendation to continue DAPT for one 
year following ACS regardless of the treatment adopted [4]. This might be partially explained 
by the fact that these recommendations have gained popularity after ART recruitment. We 
observed that subjects with unstable angina showed a larger benefit from DAPT although this 
result was not statistically significant. We also found that a non-significant trend toward better 
outcomes with DAPT in subjects undergoing off-pump surgery and those who received SVG 
but these subgroup analyses were largely underpowered to detect significant difference.  
It has been demonstrated that off-pump CABG is associated with hypercoagulability postop-
eratively [26] which can affect graft patency rate in particular with saphenous vein graft. These 
patients may benefit more from DAPT than patients operated with conventional surgery alt-
hough there is still paucity of evidence with conflicting results reported [24,27].  
 There are several limitations of the present study. Although a post-hoc power calculation sug-
gested that the present analysis was sufficiently powered to detect a difference in the primary 
endpoint (MACCE at 1 year) between the two groups. Subgroup analyses including subjects 
presenting with unstable angina or receiving off-pump surgery or SVGs were largely under-
powered. Despite PS matching, a residual imbalance cannot be excluded. In particular, we no-
ticed that the rate of reintervention was higher in patients discharged on DAPT. This might 
partially due to higher prevalence of risk factors for further coronary interventions in this 
group. Finally only 31% of subjects initially prescribed on DAPT completed 1 year of treat-
ment and this aspect might have underestimated the effect of DAPT.  No data were available 
on DAPT duration in subjects who discontinued DAPT and therefore we were unable to dis-
criminate the effect of short (3-6 months) versus long (1 year) DAPT. We performed a sensi-
tivity analysis including only subjects who completed 1 year of DAPT and DAPT was con-
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firmed to not be associated with better outcomes. We observed that the vast majority of bleed-
ing occurred during the first two months from discharge thus supporting the hypothesis that 
also short term DAPT following CABG may increase the risk of bleeding.   
In conclusion, based on these findings, there is no evidence of a significant benefit from DAPT 
with clopidogrel over aspirin alone following CABG. However, the present analysis was un-
derpowered to investigate the effect of DAPT in high risk subgroups such as patients with 
ACS. Large prospective RCTs evaluating the use of DAPT post-CABG with higher intensity 
P2Y12 antagonists are urgently needed to provide more definitive guidance for clinicians. 
Funding statement: None 
Conflict of interest: none declared. 
Figures Legends 
Figure 1. Standardized mean difference (SMD) for baseline variables before and after pro-
pensity score matching. (DAPT: dual antiplatelet therapy; SMD: standardized mean differ-
ence; PS: propensity score; BMI: body mass index; DM: diabetes mellitus; COPD: chronic 
obstructive pulmonary disease. PVD: peripheral vascular disease; MI: myocardial infarction; 
PCI: percutaneous coronary intervention; UA: unstable angina; LVEF: left ventricular ejec-
tion fraction; AF: atrial fibrillation; SVG: saphenous vein graft; OPCAB: off-pump coronary 
artery bypass; VKA: Vitamin K antagonist; BB: beta-blocker; ACEI: angiotensin converting 
enzyme inhibitor; ARB: angiotensin receptor blocker) 
Figure 2. Cumulative incidence with relative 95% confidence bands of major cerebrovascular 
and cardiac events (MACCE, right) and of composite of cardiac death/myocardial infarction 
(MI) and cerebrovascular accident (left) in patients discharged on dual antiplatelet therapy 
(DAPT) or aspirin alone.  
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Figure 3. Cumulative incidence with relative 95% confidence bands of bleeding requiring 
hospitalization in patients discharged on dual antiplatelet therapy (DAPT) or aspirin alone.  
Supplementary Figure 1. Proportional hazard assumption tested by graphical inspection using 
log(-log(S)) method with Kaplan Meier estimators from the matched sample.  
Supplementary Figure 2. Graphical representation of post-hoc power calculation for the pri-
mary end-point.   
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Table 1. Baseline and operative characteristics of patients discharged on dual antiplatelet 
therapy (DAPT) or aspirin alone.  
 DAPT Aspirin 
(unmatched) 
SMD Aspirin 
(PS-matched) 
SMD 
n  609 2308  609  
Age (mean (sd))  62.9 (9.4) 62.9 (8.7) 0.006 63.3(8.4) 0.052 
Female n(%) 73 (12.0) 331 (14.3) 0.070 78 (12.8) 0.025 
BMI (mean (sd))  27.9(4.4) 28.3(3.9) 0.110 28.0 (4.0) 0.027 
Creatinine (mean (sd))  101.2 (19.3) 95.1 (21.3) 0.301 101.2 (23.1) 0.001 
DM n(%) 164 (26.9) 531 (23.0) 0.091 158 (25.9) 0.022 
Smoking n(%) 86 (14.1) 334 (14.5) 0.010 75 (12.3) 0.053 
COPD n(%) 47 ( 7.7) 131 ( 5.7) 0.082 42 ( 6.9) 0.032 
PVD n(%) 49 ( 8.0) 152 ( 6.6) 0.056 50 ( 8.2) 0.006 
Prior stroke n(%) 13 ( 2.1) 68 ( 2.9) 0.052 12 ( 2.0) 0.012 
LVEF<.50 n(%) 136 (22.3) 582 (25.2) 0.068 141 (23.2) 0.020 
LMD n(%)  112 (18.4) 498 (21.6) 0.080 134 (22.0) 0.090 
MI within 1Y n(%) 149 (24.5) 541 (23.4) 0.024 156 (25.6) 0.027 
PCI within 1Y n(%) 28 (4.6) 265 (11.5) 0.255 32 ( 5.3) 0.030 
UA n(%) 252 (41.4) 726 (31.5) 0.207 236 (38.8) 0.054 
Preop aspirin n(%) 534 (87.7) 1989 (86.2) 0.045 539 (88.5) 0.025 
Preop clopidogrel n(%)  236 (38.8) 462 (20.0) 0.420 210 (34.5) 0.089 
OPCAB n(%) 430 (70.6) 760 (32.9) 0.814 423 (69.5) 0.025 
SVG n(%) 496 (81.4) 1751 (75.9) 0.136 491 (80.6) 0.021 
N grafts (mean (sd))  3.3 (0.9) 3.1 (0.8) 0.224 3.3 (0.9) 0.038 
Postop VKA n(%)  6 ( 1.0) 87 ( 3.8) 0.184 10 ( 1.6) 0.058 
Postop BB n(%)  501 (82.3) 1949 (84.4) 0.059 501 (82.3) <0.001 
Postop Statins n(%)  581 (95.4) 2118 (91.8) 0.149 578 (94.9) 0.023 
Postop ACEI/ARB n(%)  359 (58.9) 1130 (49.0) 0.201 348 (57.1) 0.037 
DAPT: dual antiplatelet therapy; SMD: standardized mean difference; PS: propensity score; 
BMI: body mass index; DM: diabetes mellitus; COPD: chronic obstructive pulmonary disease. 
PVD: peripheral vascular disease; MI: myocardial infarction; PCI: percutaneous coronary in-
tervention; UA: unstable angina; LVEF: left ventricular ejection fraction; AF: atrial fibrillation; 
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SVG: saphenous vein graft; OPCAB: off-pump coronary artery bypass; VKA: Vitamin K an-
tagonist; BB: beta-blocker; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin 
receptor blocker
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Table 2. Outcomes in matched patients discharged on dual antiplatelet therapy (DAPT) or as-
pirin alone.  
 DAPT Aspirin 
(matched) 
DAPT effect* 
N 609 609  
MACCE n(%) 34(5.6) 34(5.6) 0.97[0.59-1.59] 
CV death/MI/CVA n(%) 21(3.5) 29(4.8) 0.71[0.40-1.27] 
Mortality n(%) 7(1.2) 9(1.5) 0.78[0.29-2.1] 
CV mortality n(%) 5(0.8) 8(1.3) 0.63[0.21-1.91] 
MI n(%) 11(1.8) 13(2.1) 0.84[0.37-1.90] 
CVA n(%) 9(1.5) 12(2.0) 0.75[0.31-1.78] 
Repeat revascularization n(%) 17(2.7) 9(1.5) 1.91[0.85-4.33] 
*Estimates obtained with Cox models stratified by PS-matched pairs and competing risk frame-
work for MI, CVA and repeat revascularization.   
DAPT: dual antiplatelet therapy; MACCE: major cardiac and cerebrovascular events; CV-
death: cardiovascular death; MI: myocardial infarction; CVA: cerebrovascular accident   
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